急性等容血液稀释联合不同效应室浓度舒芬太尼靶控输注的安全性及术中血液保护作用  被引量:4

Safety and effect of acute normovolemic hemodilution combined with target-controlled infusion of Sufentanil at various effect-site concentrations

在线阅读下载全文

作  者:王庚[1] 何锡强[1] 

机构地区:[1]北京积水潭医院麻醉科,北京100035

出  处:《中国医药导报》2014年第20期79-84,共6页China Medical Herald

摘  要:目的探讨靶控输注(TCI)不同效应室浓度(Cet)舒芬太尼时急性等容血液稀释(ANH)的安全性及其术中血液保护作用。方法选取2011年3月~2013年1月择期于北京积水潭医院全麻下行双侧髋关节置换手术的患者84例,随机分为4组,每组各21例。诱导使用丙泊酚TCI及维库溴铵,分别TCI舒芬太尼至Cet为0.2 ng/mL(S1组)、0.4 ng/mL(S2组及C组)、0.6 ng/mL(S3组),C组患者术中不进行ANH。记录入室时及诱导前、TCI舒芬太尼前、舒芬太尼达Cet时、采血前(T0)、采血5 min(T1)、10 min(T2)、15 min(T3)、20 min(T4)、25 min(T5)、30 min(T6)、35 min(T7)、40 min(T8)时心率(HR)、动脉血压(MAP)及脑电双谱指数(BIS)值,记录入院时、采血前及采血完成后的血细胞比容(HCT)值;记录患者术中出血量及输血量。结果①4组患者达舒芬太尼Cet时HR值均较达丙泊酚Cet时显著下降[S1组:(96.0±16.2)次/min比(84.1±16.1)次/min;S2组:(94.5±12.2)次/min比(80.1±13.0)次/min;C组:(88.6±18.4)次/min比(74.2±10.8)次/min;S3组:(90.9±24.4)次/min比(76.3±12.1)次/min],差异均有统计学意义(P〈0.05);4组患者舒芬太尼给药前、后MAP差异均无统计学意义(P〉0.05)。S3组患者达舒芬太尼Cet时BIS值显著低于S1、S2及C组患者,差异有高度统计学意义(P〈0.01),且较达丙泊酚Cet时显著降低(P〈0.05),而S1、S2及C组患者未发现BIS值的显著变化。②S1、S2、S3组患者稀释前HCT、稀释后HCT及采血量、采血时间比较差异无统计学意义(P>0.05);S1、S2、S3组患者不同采血时间点BIS比较差异无统计学意义(P>0.05)。③S1、S2、S3组患者分别进行组内比较,T0~T8时间点其HR、MAP及BIS值比较差异均无统计学意义(P〉0.05)。④与S1、S2及S3组患者比较,C组患者术中出血量明显增多(P=0.001);C组患者异体输血量明显�Objective To investigate the safety and the effect of acute normovolemic hemodilution(ANH) when targetcontrolled infusion(TCI) of sufentanil at various effect-site concentrations(Cet) was given. Methods 84 patients undergoing bilateral hip replacement selective operation in Beijing Jishuitan Hospital from March 2011 to January 2013 were selected and divided into 4 groups with 21 cases in each group. Propofol TCI and Vecuronium were given for anesthesia induction, Sufentanil TCI was Cet of 0.2 ng/mL(group S1), 0.4 ng/mL(group S2, group C) and 0.6 ng/mL(group S3)respectively, ANH was not used in group C. HR, MAP and BIS value were recorded after entering operating-room and before induction(baseline values), before TCI of Sufentanil, Sufentanil at target of Cet, before blood sampling(T0),blood sampling 5 min(T1), blood sampling 10 min(T2),blood sampling 15 min(T3), blood sampling 20 min(T4),blood sampling 25 min(T5), blood sampling 30 min(T6),blood sampling 35 min(T7), blood sampling 40 min(T8).HCT value was recorded on admission, before and after blood sampling. The amount of blood loss and bloo d transfusion were recorded. Results ① The HR value inthe 4 groups at Sufentanil Cet were all lower than those at Propofol Cet [group S1:(96.0±16.2) times/min vs(84.1±16.1) times/min; group S2:(94.5±12.2) times/min vs(80.1±13.0) times /min; group C:(88.6±18.4) times/min vs(74.2±10.8) times/min; group S3:(90.9±24.4) times /min vs(76.3±12.1) times/min], the differences were statistically significant(P〉0.05). The difference of MAP in the 4 groups before and after the Sufentanil was not statistically significant(P〈0.05). The BIS value in group S3 at Sufentanil Cet were all lower than those in group S1, group S2 and group C, the differences were statistically significant(P〈0.01), and all lower than those at Propofol Cet(P 0.05), no significant change of BIS value was found in group S1, group S2

关 键 词:舒芬太尼 静脉内注射 脑电双谱指数 血流动力学现象 急性等容血液稀释 血液保护 

分 类 号:R457.1[医药卫生—治疗学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象